Posted by AGORACOM
at 4:55 PM on Thursday, September 30th, 2021
MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better. Both Into The Body and By Transportation To The World. Way Better.
For the purposes of introducing you to Mountain Valley MD (MVMD), we’ll use vaccines as an example given the state of the world since COVID-19 arrived. Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years. One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.
BUT
One thing we don’t know or understand about vaccinations is that they are only as good as:
1. The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;
2. The delivery system into your body (i.e. injection)
If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good. This is where MVMD comes in. They don’t make the vaccines, drugs or pharmaceuticals.
What they do is make their delivery better. Their physical delivery until their ultimate delivery into your body – and that is very good. By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.
A “magic bullet” is of little use without a “magic gun” – Mountain Valley MD Is The Magic Gun.
Check out these Trials & Research MVMD is accomplishing with their Vaccine technology to improve our lives:
* Expanding Oncology Work for BreastCancer using Quicksol™ technology applications
* Farm Animal Trials Using Solubilized Ivermectin
* Discovering Immediate Demand for Generic Ivermectin Uses
The latest news Involves utilizing their vaccine technology to address & develop products for the Medical Sleep Market in the U.S. strictly using cannibinoids.
Sit back and enjoy the great interview with President & CEO Dennis Hancock as he explains the developing relationship with Red White & Bloom to create products for the US sleep market.
Posted by AGORACOM-JC
at 12:17 PM on Thursday, September 30th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
How powerful is this Revolutionary & Breakthrough Green Hydrogen? Try “SCALABLE WITH NO LIMITS”
“EBH2 is scalable with no limits. It can power a small domestic generator up to ships, factories, buildings, cryptocurrency mines with high energy consumption and even cities.”
Independent validation of the technology is expected to be complete over the next 60 days. If successful, HPQ proposes to bundle the energy production capability of EBH2 systems with its silicon production to further reduce the environmental footprint of its developing high purity silicon, nano powders, and other Renewable Energy products. Moreover, if successful, EBH2 would provide HPQ with “power plant” capabilities that would allow it to produce its products anywhere on the planet.
If that wasn’t enough HPQ added the following:
“all the while opening up new, and massive addressable markets for a system that can produce cheaply green hydrogen, on demand …. The Agreement establishes the terms of the creation of a new Joint venture Company (“NEWCO”) owned by HPQ and EBH2 that will market, sell and service EBH2 systems and products in North America (Canada, Mexico, and the United States). …. units could readily replace solar panels or standby generators for homeowners.”
Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!
Posted by AGORACOM-JC
at 8:53 AM on Thursday, September 30th, 2021
Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.
The Company anticipates 65,000 visits to its clinics this year.
Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”
Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.
Posted by AGORACOM-JC
at 5:46 PM on Wednesday, September 29th, 2021
“I was blown away by FOBI “ ($KO CEO Daniel Petrov)
“Kiaro has built an amazing tech driven cannabis retail business” ($FOBI CEO Rob Anson)
If you’re a shareholder of one of these companies, here is what you need to know about each that makes this technology partnership so powerful:
KIARO is one of Canada’s largest retailers of cannabis, with 16 locations and forecasted annual revenue of $42.7 million from these locations, at a gross profit of $13.7M with further growth anticipated.
FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space. From that core technology they have built a technology stack on top of it that is second to none.
More than just talk, FOBI has completes Integrations with Lightspeed and Shopify to provide real-time Point of Sale data analytics. Moreover, they recently announced another $250.000 Data Consulting Agreement with Azincourt Energy
Posted by AGORACOM-JC
at 4:03 PM on Wednesday, September 29th, 2021
CurrencyWorks (CWRK: CSE) (CWRK: OTCQB) builds digital currencies for brands, companies, and communities to empower the free exchange of value between customers and users.
On September 24, 2021, bidding began for the Platinum and Elite NFTs. The one-of-one ZERO CONTACT Platinum Edition NFT sold for $56,860.00 USD and the ZERO CONTACT Elite Edition NFTs sold for a total of $36,575.00 USD. Additionally, CurrencyWorks receives an ongoing royalty every time these NFTs are bought and sold.
What did Cameron Chell, Chairman of CurrencyWorks have to say?
“We are extremely proud of the ZERO CONTACT NFTs that CurrencyWorks created on VUELE. This is a significant advancement for film distribution and digital collectibles,” said Cameron Chell, co-head of VUELE and Executive Chairman of CurrencyWorks.
Sit back and watch this powerful interview with company chairman Cameron Chell.
Posted by AGORACOM-JC
at 9:33 AM on Wednesday, September 29th, 2021
When 99.8% of investors read the headline to this press release, you couldn’t blame them for not understanding what it meant or how important it is to the future of POET Technologies
POET Technologies Launches Its Products and Optical Interposer Platform in China to Critical Acclaim
But this is the great thing about AGORACOM Beyond The Press Release, which provides investors with a layman’s understanding the importance of headlines like this to the business of $PTK ….
Last week in China was an important one for $PTK. The Company participated in two leading optoelectronics conferences / exhibitions in China at which they introduced POET to the China market (where most of the customers are), and demonstrated their technology across a range of products.
HOW WELL DID THE PRESENTATIONS GO?
That can easily be summarized by this powerful quote:
““The companies that attended the live demos now know who POET is and the significant value that we can provide to them. We were already engaged with a few customers, such as Fibertop and their commitment to adopt POET optical engines in their optical modules is a breakthrough for us. Other companies requested samples of our demonstrated products, and several more want to either engage in development contracts that would incorporate POET Optical Engines in their products or have POET incorporate their components into POET’s Optical Engines. Numerous opportunities for increased customer engagement in China, including with some of the largest players,”
WHAT KIND OF COMPANIES DID POET MEET AND DEMO THEIR PRODUCTS TO IN CHINA
More than 60 C-level and senior R&D executives representing over 20 companies, including:
Major China-based network equipment suppliers
Tier 1 transceiver module companies
Leading optical module and fiber optic companies (several of which are publicly traded)
Data center operators … and
Major multi-billion-dollar public enterprise companies seeking to expand into the optical transceiver business
You don’t have to be a computer scientist to understand the potential of these target markets. But you do have to watch this powerful interview in its entirety to understand the big picture.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.
We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).
PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies.
“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.”
Additional information on the ETF can be found here.
Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare
We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.
Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.
Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.
We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.
The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers.
“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”
A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”
Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good.
Posted by AGORACOM-JC
at 4:35 PM on Friday, September 24th, 2021
FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space. From that core technology they have built a technology stack on top of it that is second to none.
They have created multiple successful applications that, for the purposes of this interview, includes their venue management platform that has been deployed at multiple NCAA tournaments, a recent MGM Resorts Championship PGA Event in Las Vega and most recently signed a deal to bring their venue management solutions to the Canadian Hockey League, the world’s largest development hockey league With 9 Million Fan Visits in 2019.
In this interview we discuss not 1 but 3 great press releases:
Sit back and watch this powerful interview with CEO Rob Anson.
Tags: AI, Amazon, artificial intelligence, Big data, Bitcoin, covid19 Posted in Fobi AI | Comments Off on VIDEO – Fobi Is A Global Leader in Providing Real-Time Data Analytics Through Artificial Intelligence to Drive Customer Activation and Engagement
Posted by AGORACOM
at 1:43 PM on Friday, September 24th, 2021
How much is the market for psychedelics going to be worth?
According to one report published earlier this year by Data Bridge Market Research, it will reach $6.9 billion by 2027. Another report, from Research and Markets, predicts it will go further, reaching $10.75 billion by 2027.
In addition: California legislators are considering decriminalizing possession and sharing of psychedelics for adults 21 and older.
That’s the market context you need to know for Delic Corp, which bills itself as a marketplace for the mainstream to access psychedelic wellness.
Delic owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms, including:
Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology
MeetDelic, the premiere psychedelic wellness event, which takes place in Las Vegas this year in November
and Ketamine Infusion Centers, one of the largest ketamine clinics in the United States
In May, Delic acquired Complex Biotech Discovery Ventures (CBDV), a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development, for $7m USD, changing its name to Delic Labs.
In June, Delic paid $3m USD to acquire Ketamine Infusion Centers, a limited liability corporation formed under the laws of Arizona, which owns and operates ketamine infusion treatment clinics in Phoenix, Arizona and in Bakersfield, California.
And now, Delic has this month entered into a binding merger with Ketamine Wellness Centers (KWC) Arizona, which operates 10 ketamine infusion treatment clinics across the U.S., in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada Texas and Washington.
The deal and the national presence will bring psychedelic wellness treatment to the masses, and makes Delic the largest psychedelic wellness chain in the United States.
Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development
Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage
KWC has been operating profitably and expanding significantly with 2020 revenues in excess of $3.5m USD, on track for $4.5m USD in 2021
Joining Ketamine Infusion Centers (acquired June, 2021), which has grown steadily with revenues in excess of $4.2m USD since 2019
We sat down with Matt Stang, Delic’s CEO, to delve further into the acquisition…
Posted by AGORACOM-JC
at 5:22 PM on Thursday, September 23rd, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
The company recently released Q3 results and highlights:
· Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
· Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
· Record 9 months revenues at $10.2 million , up 94%.
· Private and public reimbursement coverage expanding for Redesca®
· New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
